麗珠醫藥(01513.HK)與健康元成立合夥企業
格隆匯11月28日丨麗珠醫藥(01513.HK)公佈,於2022年11月28日,公司與健康元訂立合夥協議,據此,公司與健康元同意以現金投資的方式成立合夥企業。
合夥企業的註冊資本為人民幣10億元,其中(i)人民幣1,000萬元將由公司與健康元分別以現金出資人民幣600萬元及人民幣400萬元成立的普通合夥人出資;(ii)人民幣5.94億元將由公司以現金出資;及(iii)人民幣3.96億元將由健康元以現金出資。因此,公司及健康元將分別直接及間接擁有合夥企業的60%及40%權益。
合夥企業的經營目的:武漢市及其周邊地區具有較為豐富的醫療項目資源以及人才資源,通過合夥企業進行戰略投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.